Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 10/20 | 0.57 |
| ▸ | POLB | P06746 | 3/20 | 0.57 |
| ▸ | TP53 | P04637 | 3/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.51 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6794794 | 0.87 | CAPN1 (0.57) | MAPTPOLBTP53SMN1; SMN2HSD11B1 | |
| SCHEMBL10805936 | 0.82 | PTGS1 (0.53) | MAPTPOLBTP53SMN1; SMN2HSD11B1 | |
| SCHEMBL30218271 | 0.82 | HSD11B1 (0.73) | HSD11B1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL6796426 | 0.82 | HSD11B1 (0.73) | HSD11B1CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL6795739 | 0.82 | HSD11B1 (0.49) | MAPTPOLBTP53SMN1; SMN2HSD11B1 | |
| SCHEMBL1726225 | 0.81 | MAPT (0.80) | MAPTPOLBTP53SMN1; SMN2HSD11B1 | |
| SCHEMBL6792108 | 0.80 | HSD11B1 (0.55) | MAPTPOLBTP53SMN1; SMN2HSD11B1 | |
| SCHEMBL7334969 | 0.78 | HSD11B1 (0.55) | MAPTPOLBTP53SMN1; SMN2HSD11B1 | |
| SCHEMBL11037232 | 0.78 | PTGS1 (0.72) | MAPTPOLBTP53SMN1; SMN2HSD11B1 | |
| SCHEMBL1727186 | 0.77 | MAPT (0.61) | MAPTPOLBTP53SMN1; SMN2HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040063696-A1 | 1,1-dioxo-2h-1,2-benzothiazine-3-carboxamide derivatives,method for preparing same and pharmaceutical compositions comprising same | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) | 2004-04-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040063696-A1 | 1,1-dioxo-2h-1,2-benzothiazine-3-carboxamide derivatives,method for preparing same and pharmaceutical compositions comprising same | ADCY2, ADCY1, HRH2 | MAPT 4376/4885POLB 4037/4885TP53 4727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.